TSS
MYGN icon

Two Sigma Securities’s Myriad Genetics MYGN Stock Holding History

Two Sigma Securities’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-13,029
Closed -$440K – 2883
2018
Q1 		$385K Buy
+13,029
New +$441K ﹤0.01% 1844

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Securities's MYGN Position: Q2 2018 in Review

Two Sigma Securities sold out of Myriad Genetics (MYGN) in Q2 2018, closing a stake of 13,029 shares — an estimated $440K sold.

Two Sigma Securities first reported a position in MYGN in Q1 2018 and held it in 1 quarter. The position peaked at $385K in Q1 2018. 258 funds tracked by Wall St. Rank hold MYGN as of Q2 2018.

  • Two Sigma Securities reported no remaining Myriad Genetics position as of Q2 2018 after selling out during the quarter.
  • Two Sigma Securities sold 13,029 Myriad Genetics shares in Q2 2018, an estimated $440K.
  • Two Sigma Securities first reported a position in Myriad Genetics in Q1 2018 and held it in 1 quarter.
  • Two Sigma Securities's Myriad Genetics position peaked at $385K in Q1 2018.
  • 258 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2018.

Based on Two Sigma Securities's 13F filing for Q2 2018, filed 14 Aug 2018.